Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CM336 + isatuximab
- Development stage
- Phase 2
- Lead developer
- Keymed Biosciences
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
CM336 + isatuximab is a combination therapy being investigated for the treatment of newly diagnosed multiple myeloma (NDMM), particularly in patients with severe renal impairment. CM336 is a bispecific antibody that targets B-cell maturation antigen (BCMA) on plasma cells and CD3 on T cells, acting as a T-cell engager to facilitate the direct lysis of malignant cells. Isatuximab is a monoclonal antibody that targets CD38, a glycoprotein highly expressed on myeloma cells, inducing cell death through multiple pathways including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct apoptosis. This combination aims to provide a synergistic anti-tumor effect by targeting two distinct myeloma-associated antigens and engaging different arms of the immune system.
- Other names
- CM336 Plus IsatuximabCM-336 Plus IsatuximabCM 336 Plus Isatuximab
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on CM336 + isatuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CM336 + isatuximab.